natgillin/translations-raw huggingface dataset:
The CHMP concluded that, in accordance with EU requirements, Desloratadine ratiopharm has been shown to have comparable quality and to be bioequivalent to Aerius.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Desloratadine ratiopharm primerljivo raven kakovosti kot zdravilo Aerius ter da mu je biološko enakovredno.
What are the benefits and risks of Desloratadine ratiopharm?
Kakšne so koristi in tveganja, povezani z zdravilom Desloratadine ratiopharm?
Desloratadine ratiopharm is a ‘generic medicine'.
Desloratadine ratiopharm je „generično zdravilo“.
The Committee recommended that Desloratadine ratiopharm be given marketing authorisation.
Odbor je zato priporočil, da se za zdravilo Desloratadine ratiopharm odobri dovoljenje za promet.
Desloratadine ratiopharm is a medicine containing the active substance desloratadine.
Desloratadine ratiopharm je zdravilo, ki vsebuje zdravilno učinkovino desloratadin.
The active substance in Desloratadine ratiopharm, desloratadine, is an antihistamine.
Zdravilna učinkovina zdravila Desloratadine ratiopharm je desloratadin, ki je antihistaminik.
Why has Desloratadine ratiopharm been approved?
Zakaj je bilo zdravilo Desloratadine ratiopharm odobreno?
How has Desloratadine ratiopharm been studied?
Kako je bilo zdravilo Desloratadine ratiopharm raziskano?
What is Desloratadine ratiopharm used for?
Za kaj se zdravilo Desloratadine ratiopharm uporablja?
It works by blocking the receptors to which histamine, a substance in the body that causes allergic symptoms,
Desloratadin deluje kot zaviralec receptorjev, na katere se običajno veže histamin, tj. snov v telesu, ki stran 2/2
What is Desloratadine ratiopharm?
Kaj je zdravilo Desloratadine ratiopharm?
How is Desloratadine ratiopharm used?
Kako se zdravilo Desloratadine ratiopharm uporablja?
How does Desloratadine ratiopharm work?
Kako zdravilo Desloratadine ratiopharm deluje?
This summary was last updated in 12-2017.
Povzetek je bil nazadnje posodobljen 12-2017.
The European Commission granted a marketing authorisation valid throughout the European Union for Cubicin on 19 January 2006.
Evropska komisija je dovoljenje za promet z zdravilom Cubicin, veljavno po vsej Evropski uniji, izdala 19. januarja 2006.
What measures are being taken to ensure the safe and effective use of Cubicin?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Cubicin?
It can stop the growth of certain types of bacteria by attaching to the membrane surrounding the bacterial cell and upsetting the essential functions that keep the cell alive.
Ta lahko ustavi rast določenih vrst bakterij tako, da se veže na membrano, ki obdaja bakterijsko celico, in s tem prepreči bistvene funkcije, ki omogočajo preživetje celice.
The full EPAR for Cubicin can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Cubicin je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
This is a summary of the European public assessment report (EPAR) for Cubicin.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Cubicin.
Effectiveness varied between the two studies because of differences in the types of patients and infections being treated.
Učinkovitost je bila med študijama drugačna zaradi razlik v vrstah bolnikov in zdravljenih okužb.
Cubicin is an antibiotic medicine, which is used to treat the following bacterial infections:
Cubicin je antibiotično zdravilo, ki se uporablja za zdravljenje naslednjih bakterijskih okužb:
The duration of treatment with Cubicin depends on the risk of complications and official recommendations.
Trajanje zdravljenja z zdravilom Cubicin je odvisno od tveganja za zaplete in uradnih priporočil.
‘Complicated' means that the infection is difficult to treat, because it has spread to the deep tissues below the skin, treatment with surgery might be needed, or the patient has other conditions that might affect how well treatment works;
„Zapleteno“ pomeni, da je okužbo težko zdraviti, ker je razširjena v tkiva globoko pod kožo, ker je morda potreben kirurški poseg ali ker ima bolnik še druga obolenja, ki utegnejo vplivati na zdravljenje;
Other information about Cubicin
Druge informacije o zdravilu Cubicin
Prescribers should consider official guidance on the use of antibiotics.
Zdravniki, ki predpisujejo zdravilo, morajo upoštevati uradne smernice o uporabi antibiotikov.
In the first two studies involving 1,118 adults with complicated skin and soft tissue infections (mainly wound infections and major abscesses), Cubicin was effective in 67% of patients in one study and in 85% in the other.
V prvih dveh študijah, ki sta vključevali 1 118 odraslih z zapletenimi oblikami okužb kože in mehkih tkiv (v glavnem okužbami ran in večjimi abscesi), je bilo zdravilo Cubicin v eni študiji učinkovito pri 67 % bolnikov, v drugi pa pri 85 %.
• complicated infections of the skin and soft tissue below the skin in patients from 1 year of age.
• zapletenih oblik okužbe kože in mehkih tkiv pod kožo pri bolnikih, starejših od enega leta.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Cubicin have also been included in the summary of product characteristics and the package leaflet.
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Cubicin upoštevati zdravstveni delavci in bolniki, so vključeni tudi v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
The European Medicines Agency decided that Cubicin's benefits are greater than its risks and recommended that it be given marketing authorisation.
Evropska agencija za zdravila je sklenila, da so koristi zdravila Cubicin večje od z njim povezanih tveganj, in priporočila, da se zanj izda dovoljenje za promet.
Three main studies in adults and two in children aged between 1 and 17 years found that Cubicin was as effective as standard treatments at curing or improving infection.
S tremi glavnimi študijami pri odraslih in dvema pri otrocih, starih od enega do 17 let, so ugotovili, da je zdravilo Cubicin pri zdravljenju ali izboljšanju okužb enako učinkovito kot standardno zdravljenje.
What benefits of Cubicin have been shown in studies?
Kakšne koristi je zdravilo Cubicin izkazalo v študijah?
The decision to treat this type of infection with Cubicin should be based on the likelihood that the medicine will work against the infection and on advice from an expert;
Odločitev o zdravljenju te vrste okužbe z zdravilom Cubicin mora temeljiti na verjetnosti, da bo to delovalo proti okužbi, ter nasvetu strokovnjaka;
What is Cubicin and what is it used for?
Kaj je zdravilo Cubicin in za kaj se uporablja?
What are the risks associated with Cubicin?
Kakšna tveganja so povezana z zdravilom Cubicin?
The first study in children and adolescents involved 396 patients with complicated skin and soft tissue infections without bacteraemia.
Prva študija pri otrocih in mladostnikih je vključevala 396 bolnikov z zapletenimi oblikami okužbe kože in mehkih tkiv brez bakteriemije.
It is used in adults when the bacteraemia is associated with either of the two infections above, or in adolescents and children from 1 year of age when the bacteraemia is associated with complicated infections of the skin and soft tissue.
Uporablja se pri odraslih, kadar je bakteriemija povezana s katero od zgoraj omenjenih okužb, ali pri mladostnikih in otrocih, starejših od enega leta, kadar je bakteriemija povezana z zapletenimi okužbami kože in mehkih tkiv.
The company that markets Cubicin will provide all doctors who are expected to use Cubicin with a dosage card to ensure the safe use of the medicine.
Družba, ki trži zdravilo Cubicin, bo vsem zdravnikom, ki bodo predpisovali to zdravilo, priskrbela kartico s predpisanimi odmerki, s čimer bo zagotovila varno uporabo zdravila.
It is not intended to provide practical advice on how to use Cubicin.
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
The most common side effects with Cubicin (seen in between 1 and 10 patients in 100) are infections caused by fungi (moulds and yeasts), urinary tract infections (infection of the structures that carry urine), Candida infection (a fungal infection), anaemia (low red blood cell counts), anxiety, insomnia (difficulty sleeping), dizziness, headache, hypertension (high blood pressure), hypotension (low blood pressure), gastrointestinal and abdominal pain (belly ache), nausea (feeling sick), vomiting, constipation, diarrhoea, flatulence (gas), bloating and distension (feeling as if the tummy is full), rash, pruritus (itching), pain in the limbs (arms or legs), infusion site reactions, pyrexia (fever), asthenia (weakness), abnormal liver tests and raised levels in the blood of an enzyme called CPK (a marker of muscle damage).
Najpogostejši neželeni učinki zdravila Cubicin (ki se pojavijo pri 1 do 10 bolnikov od 100) so glivične okužbe (okužbe, ki jih povzročajo plesni in kvasovke), okužbe sečil (okužbe struktur za odvajanje urina), okužbe s kandido (glivična okužba), anemija (nizko število rdečih krvnih celic), anksioznost, insomnija (nespečnost), omotica, glavobol, hipertenzija (visok krvni tlak), hipotenzija (nizek krvni tlak), bolečine v prebavilih in trebuhu, navzeja (siljenje na bruhanje), bruhanje, zaprtje, driska, vetrovi, napenjanje in napihnjenost (občutek polnega trebuha), izpuščaj, pruritus (srbečica), bolečine v okončinah (rokah ali nogah), reakcije na mestu infundiranja, pireksija (povišana telesna temperatura), astenija (šibkost), nenormalni rezultati jetrnih testov ter povišane ravni krvnega encima, imenovanega CPK (označevalec poškodb mišic).
There was insufficient evidence to support the use of Cubicin to treat bacteraemia in patients who did not have either right-sided infective endocarditis or complicated skin and softtissue infections.
Ni bilo dovolj dokazov v podporo uporabi zdravila Cubicin za zdravljenje bakteriemije pri bolnikih, ki niso imeli bodisi infektivnega endokarditisa desne strani bodisi zapletenih oblik okužbe kože ali mehkih tkiv.
Why is Cubicin approved?
Zakaj je bilo zdravilo Cubicin odobreno?
The third study involved 246 adults with bacteraemia caused by S. aureus, including 35 who also had right-sided infective endocarditis.
V tretjo študijo je bilo vključenih 246 odraslih z bakteriemijo, ki jo je povzročila bakterija S. aureus, vključno s 35 bolniki, ki so imeli tudi infektivni endokarditis desne strani.
• right-sided infective endocarditis (infection of the lining or the valves of the right side of the heart) caused by the bacterium Staphylococcus aureus (S. aureus) in adults.
• infektivnega endokarditisa desne strani (okužbe sluznice ali zaklopk na desni strani srca), ki ga povzroča bakterija Staphylococcus aureus (S. aureus) pri odraslih.
Standard treatments comprised use of antibiotics such as vancomycin, a penicillin (including oxacillin, cloxacillin, flucloxacillin and nafcillin) or a cephalosporin.
Standardno zdravljenje zajema uporabo antibiotikov, kot so vankomicin, penicilin (vključno z oksacilinom, kloksacilinom, flukloksacilinom in nafcilinom) ali cefalosporin.
The second study in children and adolescents involved 73 patients with bacteraemia caused by S. aureus.
Druga študija pri otrocih in mladostnikih je vključevala 73 bolnikov z bakteriemijo, ki jo je povzročila bakterija S. aureus.
• bacteraemia (infection of the blood) caused by S. aureus.
• bakteriemije (okužbe krvi), ki jo povzroča bakterija S. aureus.
For more information about treatment with Cubicin, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Cubicin preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Cubicin is given by infusion lasting 60 minutes in children aged 1 to 6 years and 30 minutes in those aged above 7 years.
Zdravilo Cubicin se pri otrocih, starih od enega do šest let, daje z infundiranjem, ki traja 60 minut, pri otrocih, starejših od sedem let, pa 30 minut.
The active substance in Cubicin, daptomycin, is an antibiotic that belongs to the group ‘lipopeptides'.
Zdravilna učinkovina zdravila Cubicin, daptomicin, je antibiotik, ki spada v skupino lipopeptidov.
For practical information about using Cubicin, patients should read the package leaflet or contact their doctor or pharmacist.
Za praktične informacije o uporabi zdravila Cubicin naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
Cubicin is given into a vein as an infusion lasting 30 minutes or as an injection lasting 2 minutes.
Zdravilo Cubicin se daje v veno z infundiranjem, ki traja 30 minut, ali z injiciranjem v trajanju dveh minut.
For the full list of side effects and restrictions with Cubicin, see the package leaflet.
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Cubicin glejte navodilo za uporabo.
Serious side effects include hypersensitivity (allergic) reactions, eosinophilic pneumonia (infection of the lungs), drug rash with eosinophilia and systemic symptoms (DRESS, a severe reaction affecting the skin, blood and internal organs), angioedema (rapid swelling of deeper skin tissues) and rhabdomyolysis (breakdown of muscle fibres).
Resni neželeni učinki vključujejo preobčutljivostne (alergijske) reakcije, eozinofilno pljučnico (okužbo pljuč), z zdravilom povezan izpuščaj z eozinofilijo in sistemskimi simptomi (DRESS, huda reakcija, ki prizadene kožo, kri in notranje organe), angioedem (hitro otekanje globokih kožnih tkiv) in rabdomiolizo (razgradnjo mišičnih vlaken).
Cubicin is available as a powder that is made up into a solution for injection or infusion (drip) into a vein.
Zdravilo Cubicin je na voljo v obliki praška za pripravo raztopine za injiciranje ali infundiranje (kapalne infuzije) v veno.
In the group with endocarditis, treatment was successful in 42% (8 out of 19) of the patients receiving Cubicin compared with 44% (7 out of 16) of the patients receiving standard treatment.
V skupini z endokarditisom je bilo zdravljenje uspešno pri 42 % (8 od 19) bolnikov, ki so prejemali zdravilo Cubicin, in pri 44 % (7 od 16) bolnikov, ki so prejemali standardno zdravljenje.
Treatment was successful in 88% (227 out of 257) of the patients receiving Cubicin compared with 86% (114 out of 132) receiving standard treatment.
Zdravljenje je bilo uspešno pri 88 % (227 od 257) bolnikov, ki so prejemali zdravilo Cubicin, in pri 86 % (114 od 132) bolnikov, ki so prejemali standardno zdravljenje.
Cubicin contains the active substance daptomycin.
Zdravilo Cubicin vsebuje zdravilno učinkovino daptomicin.
Treatment was successful in 88% (45 out of 51) of the patients receiving Cubicin compared with 77% (17 out of 22) receiving standard treatment.
Zdravljenje je bilo uspešno pri 88 % (45 od 51) bolnikov, ki so prejemali zdravilo Cubicin, in pri 77 % (17 od 22) bolnikov, ki so prejemali standardno zdravljenje.
In children the dose of Cubicin for skin or soft tissue infection without bacteraemia depends on the child's age and ranges between 5 and 10 mg/kg once a day.
Pri otrocih je odmerek zdravila Cubicin pri okužbah kože ali mehkih tkiv brez bakteriemije odvisen od njihove starosti in znaša med 5 in 10 mg/kg enkrat na dan.
How is Cubicin used?
Kako se zdravilo Cubicin uporablja?
How does Cubicin work?
Kako zdravilo Cubicin deluje?
For endocarditis and for skin or soft tissue infection with bacteraemia, the dose is 6 mg/kg once a day.
Pri endokarditisu ali okužbah kože oziroma mehkih tkiv z bakteriemijo znaša odmerek 6 mg/kg enkrat na dan.
In adults, for skin or soft tissue infections without bacteraemia, Cubicin is given at a dose of 4 mg/kg body weight once a day.
Pri odraslih se pri okužbah kože ali mehkih tkiv brez bakteriemije zdravilo Cubicin daje v odmerku 4 mg/kg telesne mase enkrat na dan.
Higher doses (between 7 and 12 mg/kg once a day) are used if the skin or soft tissue infection is associated with bacteraemia.
Če je okužba kože ali mehkih tkiv povezana z bakteriemijo, se uporabljajo večji odmerki (med 7 in 12 mg/kg enkrat na dan).
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom sedation and analgesia depend on the dose that is used.
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom od njihove telesne mase.
It also depends on the use and the way it is given.
Odmerek je odvisen tudi od uporabe in načina dajanja zdravila.
• as premedication before inducing general anaesthesia.
• kot premedikacija, ki se daje pred uvedbo splošne anestezije.
The full EPAR for Cepedex can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila Cepedex je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
It works by attaching to receptors known as alpha2-adrenergic receptors and preventing the release of the neurotransmitter noradrenaline from nerve cells in the body.
Deluje tako, da se veže na receptorje, imenovane alfa2-adrenoreceptorji, in preprečuje sproščanje živčnega prenašalca noradrenalina iz živčnih celic v telesu.
This is a summary of the European public assessment report (EPAR) for Cepedex.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Cepedex.
The Agency's Committee for Medicinal Products for Veterinary Use (CVMP) concluded that, in accordance with EU requirements, Cepedex has been shown to have comparable quality to Dexdomitor.
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) pri agenciji je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Cepedex primerljivo raven kakovosti kot zdravilo Dexdomitor.
Cepedex is an alpha2-adrenoceptor agonist.
Zdravilo Cepedex je agonist alfa2-adrenoreceptorja.
The company provided information on the quality and manufacture of Cepedex.
Družba je priskrbela podatke o kakovosti in proizvodnji zdravila Cepedex.
• when carrying out mildly to moderately painful procedures and examinations that require the animal to be restrained or sedated and made less sensitive to pain (analgesia).
• pri blago do zmerno bolečih posegih in pregledih, pri katerih so potrebni mirovanje in sedacija živali ter zmanjšanje občutljivosti za bolečino (analgezija).
Cepedex is a medicine used to sedate (calm down) dogs and cats in the following situations:
Zdravilo Cepedex se uporablja za sedacijo (pomiritev) psov in mačk v naslednjih primerih:
What are the benefits and risks of Cepedex?
Kakšne so koristi in tveganja, povezani z zdravilom Cepedex?
The Committee recommended that Cepedex be approved for use in the EU.
Priporočil je, da se zdravilo Cepedex odobri za uporabo v EU.
For dogs the dose depends on their body surface area (calculated using bodyweight) and in cats it is based on bodyweight.
Pri psih je odmerek odvisen od njihove telesne površine (izračunane na podlagi telesne mase), pri mačkah pa
Cepedex can also be used in dogs to provide pain relief and deep sedation when carrying out medical procedures and minor surgery where it is used in combination with butorphanol (a sedative and analgesic).
Zdravilo Cepedex se lahko pri psih uporablja tudi za lajšanje bolečine in globoko sedacijo pri zdravstvenih in manjših kirurških posegih, in sicer v kombinaciji z butorfanolom (sedativom in analgetikom).
It is not intended to provide practical advice on how to use Cepedex.
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
Cepedex is used in non-invasive procedures which do not involve breaking the skin or a body cavity.
Zdravilo Cepedex se uporablja pri neinvazivnih posegih, kar pomeni, da se pri postopku ne predre kože ali stene telesne votline;
Because Cepedex is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Ker je zdravilo Cepedex generično zdravilo in je biološko enakovredno referenčnemu zdravilu, so koristi in tveganja enaki kot pri referenčnem zdravilu.
What is Cepedex and what is it used for?
Kaj je zdravilo Cepedex in za kaj se uporablja?
This means that Cepedex is similar to a ‘reference medicine' already authorised in the EU called Dexdomitor.
To pomeni, da je podobno referenčnemu zdravilu, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Dexdomitor.
Other information about Cepedex?
Druge informacije o zdravilu Cepedex
Cepedex contains the active substance dexmedetomidine and is a ‘generic medicine'.
Zdravilo Cepedex vsebuje zdravilno učinkovino deksmedetomidin in je „generično zdravilo“.
In dogs, Cepedex is given by injection into a vein or a muscle.
Psom se zdravilo Cepedex daje z injiciranjem v veno ali mišico, mačkam pa z injiciranjem v mišico.
Why is Cepedex approved?
Zakaj je bilo zdravilo Cepedex odobreno?
For more information about treatment with Cepedex, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.
Za več informacij o zdravljenju z zdravilom Cepedex naj lastniki ali skrbniki živali preberejo navodilo za uporabo ali se posvetujejo z veterinarjem ali farmacevtom.
For practical information about using Cepedex, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.
Za praktične informacije o uporabi zdravila Cepedex naj lastniki ali skrbniki živali preberejo navodilo za uporabo ali se posvetujejo z veterinarjem ali farmacevtom.
Cepedex is available as a solution for injection and can only be obtained with a prescription.
Zdravilo Cepedex je na voljo v obliki raztopine za injiciranje, predpisovanje in izdaja zdravila je le na recept.
Safety information has been included in the summary of product characteristics and the package leaflet for Cepedex, including the appropriate precautions to be followed by healthcare professionals and animal owners or keepers when giving Cepedex.
V povzetek glavnih značilnosti zdravila Cepedex in navodilo za njegovo uporabo so bile vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in lastniki ali skrbniki živali pri dajanju tega zdravila.
How does Cepedex work?
Kako zdravilo Cepedex deluje?
How has Cepedex been studied?
Kako je bilo zdravilo Cepedex raziskano?
How is Cepedex used?
Kako se zdravilo Cepedex uporablja?
No additional studies were needed as Cepedex is a generic medicine that is given by injection, is similar in composition to, and contains the same active substance as the reference medicine, Dexdomitor.
Ker je zdravilo Cepedex generično zdravilo, ki se daje z injiciranjem, je po sestavi podobno referenčnemu zdravilu Dexdomitor in tudi vsebuje isto zdravilno učinkovino, niso bile potrebne nobene dodatne študije.
The European Commission granted a marketing authorisation valid throughout the EU for Cepedex on 13 December 2016.
Evropska komisija je dovoljenje za promet z zdravilom Cepedex, veljavno po vsej Evropski uniji, izdala
The duration and depth of
Trajanje in globina sedacije in analgezije sta odvisna od uporabljenega odmerka.
1 pre-filled syringe of 150 mg + 2 needles, 1 prefilled syringe 100 mg + 2 needles
1 napolnjena injekcijska brizga s 150 mg + 2 igli, 1 napolnjena injekcijska brizga s 100 mg + 2 igli
Initiation pack:
Uvajalno pakiranje:
Strength Pharmaceutical Form Route of Administration
Farmacevtska oblika Pot uporabe Ovojnina
Xeplion
Jakost
Hygienic measures may reduce the risk of porcine coccidiosis.
Higienski ukrepi lahko zmanjšajo tveganje za kokcidiozo prašičev.
Iron is an essential micronutrient.
Železo je bistveno mikrohranilo.
Inject intramuscularly behind the ear into the neck.
Injicirajte intramuskularno za ušesom v vrat.
Frequent and repeated use of antiprotozoals from the same class may lead to the development of resistance.
Pogosta in ponavljajoča se uporaba antiprotozoikov; iz istega razreda lahko vodi do razvoja odpornosti.
The rubber stopper of the vial may be safely punctured up to 30 times.
Zamašek viale se lahko varno prebode do 30-krat.